Today, Physidia announces the acquisition of Nordic Medcom, its long-standing partner and distributor in the Nordic region. This transaction marks a significant milestone in Physidia’s international development and opens a new phase focused on expanding access to home hemodialysis therapy across Europe.
After several years of close collaboration, shared projects, and joint expansion of home dialysis programs, the acquisition of Nordic Medcom represents an opportunity for both parties. It is a natural step in Mats Grenner’s intention to ensure the long-term continuity and legacy of the company he founded.
A KEY NORDIC ACTOR IN DIALYSIS
Founded and led by Mats Grenner, Nordic Medcom has established a strong and trusted presence across Finland, Sweden, Norway, and Denmark. The company generates approximately €6 million in annual revenue, supports around 85 patients in home hemodialysis (HHD), and relies on a team of about fifteen professionals dedicated to nephrology care. Through multiple long-term hospital partnerships and service agreements, Nordic Medcom has become an essential stakeholder in dialysis in the region.
Beyond distributing the Physidia S³ system, Nordic Medcom has built a broader dialysis-related portfolio and strong clinical collaborations. This acquisition therefore represents not only geographic expansion, but also an opportunity to extend and structure Physidia’s therapeutic offering in the Nordic markets.
“Nordic Medcom has built deep clinical relationships and a solid presence in the region,” said Julien Dolivet, CEO of Physidia. “Mats Grenner wanted to lean back his company to a solid partner, capable to support Nordic Medcom growth. It was quite obvious for me that Physidia had a role to play.”
According to Mats Grenner “This acquisition strengthens our capacity to support healthcare professionals locally while expanding patient access to home hemodialysis”.
PHYSIDIA: 15 YEARS DEDICATED TO HOME HEMODIALYSIS
Founded in 2010 in Angers, France, Physidia has now more than 15 years of experience dedicated exclusively to home hemodialysis. Present in 18 countries, Physidia supports more than 1,400 patients worldwide, either through trusted distribution partners or direct operations. To date, over 1.3 million dialysis sessions have been performed using the S³ system.
Over the past years, the company has structured its international expansion progressively — including the recent launch of offices in Germany— selecting markets based on their potential to develop therapy access based on robust clinical standards.
This acquisition reflects that strategy: strengthening presence where therapy adoption can be expanded responsibly, in close collaboration with local healthcare systems.
ADVANCING THERAPY BEYOND TECHNOLOGY
While the S³ monitor remains central to Physidia’s expertise, the company’s commitment extends beyond the device itself.
Home hemodialysis represents a therapy model associated with improved clinical stability, enhanced quality of life, and greater patient autonomy. Expanding this model requires clinical education, long-term partnerships, logistics expertise, and structured support.
By integrating Nordic Medcom into the dialysis programs:
Strengthen long-term clinical collaborations across the Nordic region
Expand access to frequent home hemodialysis
This step reflects Physidia’s long term commitment to advancing access to home-based care, while supporting healthcare professionals in expanding patient access to home hemodialysis throughout the Nordic countries.
A DEVELOPMENT ANCHORED IN VISION AND VALUES
Physidia’s growth remains guided by its founding principles :
Our Vision: Make people’s lives better.
Our Mission: Improve health, quality of life and freedom for those who are using our innovative solutions.
The acquisition of Nordic Medcom embodies this commitment: expanding therapy access, respecting local expertise, and building long-term partnerships with integrity and patient focus. Nordic Medcom will continue to operate under the leadership of Mats Grenner, ensuring continuity for teams, healthcare partners, and patients across the Nordic region.
ABOUT NORDIC MEDCOM
Nordic Medcom’s origins date back to 1947, when Wilhelm Blumberg founded Carbonex Oy in Finland. Mats Grenner joined the family-owned company in 1994 and became Managing Director and Board Member in 1996. Under his leadership, the business expanded into nephrology, evolving from a sub-distributor of dialysis catheters to a structured dialysis actor across the Nordic region.
In 2011, Mats Grenner initiated one of the early home hemodialysis programs in the region, treating the first patients that same year. Continued growth in clinical partnerships and portfolio development led to the acquisition of Nordic Medcom AB in 2015, consolidating activities across Sweden, Denmark, Norway, and Finland. In 2024, the group structure was formalized, with Carbonex Oy becoming the parent company of Nordic Medcom AB and Nordic Medcom Oy.
Today, Nordic Medcom generates approximately €6 million in annual revenue, supports around 85 patients in home hemodialysis, and relies on a team of fifteen professionals dedicated to nephrology care. Through long-standing hospital partnerships, the company is a recognized stakeholder in dialysis across the Nordic countries.
After several years of close collaboration and joint development of home dialysis programs, the acquisition by Physidia represents a natural step to ensure the long-term continuity of the organization and preserve the legacy built by Mats Grenner.
ABOUT PHYSIDIA
Founded in Angers in 2010, Physidia has become a European leader in home hemodialysis by developing a portable monitor, the S³®. After obtaining CE marking in 2013, the company expanded its presence to 18 markets, mainly in Europe and the Middle East.
The innovative technology of the S³® monitor is specifically designed to provide high-quality, safe, and comfortable dialysis for patients at home. Today over 1,400 patients undergo dialysis daily with the S³® and more than 1.3 million sessions have been completed.
The company's rapid growth and international expansion demonstrate its ability to innovate and respond to the challenges of the healthcare market. Physidia has been named “Growth Champion” by Les Echos on several occasions, as well as “Europe's Long-Term Growth Champion” by the Financial Times.
Photo: Julien Dolivet, CEO of Physidia, and Mats Grenner, Founder of Nordic Medcom
